Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clonazepam + Mucolox is a combination formulation consisting of the benzodiazepine clonazepam and the mucoadhesive drug delivery vehicle Mucolox. Clonazepam acts as a central nervous system depressant by enhancing gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to anticonvulsant, anxiolytic, muscle relaxant, and sedative effects. In this combination, clonazepam is delivered topically to the oral mucosa using Mucolox—a proprietary mucoadhesive hydrogel designed to prolong contact time with mucosal surfaces and enhance local drug absorption. This approach aims to maximize local therapeutic effects while minimizing systemic exposure. The primary indication for this combination has been investigated in clinical trials for burning mouth syndrome (stomatodynia), where topical application of clonazepam in a mucoadhesive base may provide symptomatic relief by disrupting local pain mechanisms[1][4]. While similar formulations have been studied with other drugs (e.g., dexamethasone), evidence specifically supports the use of topical or mucoadhesive-based clonazepam for oral mucosal pain syndromes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonazepam + Mucolox.